Redeye comments on GiG’s Q1-results which were largely in line with our forecast where the company s...
Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above o...
Redeye comments on Embracer’s Q4-results which saw stronger-than-expected EBIT, driven by PC/Console...
Redeye comments on Camurus’ first quarter report 2025, which saw Buvidal sales on track, but Brixadi...
Redeye updates its view on Flexion Mobile following its Q1 2025 report, which was in line with our e...
Q1 miss mainly driven by FK and SDR Cutting '25e EBITDA/EBIT by 9/15%, small changes to '26e-'27e FV...
Fiskars hosted its "Get to know Vita" day today. The company has been building its "brand first" app...
Redeye comments on today's news that Curasight's share issue was subscribed to 47%, raising DKK47m b...
Redeye believes Lagercrantz continued its stable trend and ended fiscal year 2024/2025 in a solid fa...
Redey comments on Oncopeptides’ first quarter report 2025.
För det första kvartalet 2025 var intäkterna 39 procent lägre än Mangolds prognos.
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Utifrån en fortsatt svag marknad och orderingång under början av 2025 har vi sänkt våra förväntninga...
Redeye provides a brief comment on Kancera’s update regarding the collaboration with Recardio and th...
Underliggande tillväxt trots svagare kvartal Det första kvartalet var sammantaget svagare än motsva...
Det svenska bioteknikbolaget Aptahem AB (publ) (”Aptahem” eller ”Bolaget”) utvecklar RNA-baserade lä...
Redeye comments on Initiator Pharma’s announcements earlier today regarding its clinical expansion i...
I april 2025 lämnade EFSA (Europeiska myndigheten för livsmedelssäkerhet) ett positivt vetenskaplig...
Biofrigas Sweden AB (publ) (”Biofrigas” eller ”Bolaget”) är verksamma på den växande marknaden för f...
Organic sales decline of 9% y-o-y EBIT margin of 5.
